Concepedia

Stephan D. Kendall

SD

Statistics

Publications

3

Citations

460

H-Index

3

Active since

2012

Affiliations

Sungkyunkwan University(Current)

Stephan D. Kendall is an author at Sungkyunkwan University specializing in oncology, medicine, and oncology pharmacotherapy.

Publications per year

2012–2022

3

Publications

3

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

CH Barcenas, Sara A. Hurvitz, Jack A. Di Palma et al. · Annals of Oncology · 2020 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting eNOS in Pancreatic Cancer

Benjamin L. Lampson, Stephan D. Kendall, Brooke B. Ancrile et al. · Cancer Research · 2012 · 76 citations

Medicine, Oncology, Pharmacology +13

1–3 of 3